| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US6521212 | UNITED THERAP | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
Nov, 2018
(5 years ago) | |
| US6756033 | UNITED THERAP | Method for delivering benzindene prostaglandins by inhalation |
Nov, 2018
(5 years ago) | |
| US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(3 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(4 years from now) | |
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
Tyvaso is owned by United Therap.
Tyvaso contains Treprostinil.
Tyvaso has a total of 13 drug patents out of which 4 drug patents have expired.
Expired drug patents of Tyvaso are:
- US5153222
- US6521212
- US6756033
- US6765117
Tyvaso was authorised for market use on 30 July, 2009.
Tyvaso is available in solution;inhalation dosage forms.
Tyvaso can be used as method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device, method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device, treatment of pulmonary hypertension, treatment of pulmonary hypertension by inhalation.
The generics of Tyvaso are possible to be released after 04 January, 2042.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-856) | Mar 31, 2024 |
| M(M-145) | May 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| New Dosage Form(NDF) | Jul 30, 2012 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Treatment of pulmonary hypertension; Treatment of pulmonary hypertension by inhalation; Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a ...
Dosage: SOLUTION;INHALATION
TYVASO family patents
